Abstract
The identification of biomarkers for predicting the responsiveness to eribulin in patients with metastatic breast cancer pretreated with an anthracycline and a taxane remains an unmet need. Here, we established a serum microRNA (miRNA)-based prediction model for the emergence of new distant metastases after eribulin treatment. Serum samples were collected from metastatic breast cancer patients prior to eribulin treatment and comprehensively evaluated by miRNA microarray. The prediction model for estimating eribulin efficacy was established using the logistic LASSO regression model. Serum samples were collected from 147 patients, of which 52 developed at least one new distant metastasis after eribulin monotherapy and 95 did not develop new distant metastases. A combination of eight serum miRNAs (miR-4483, miR-8089, miR-4755-3p, miR-296-3p, miR-575, miR-4710, miR-5698 and miR-3160-5p) predicted the appearance of new distant metastases with an area under the curve of 0.79, sensitivity of 0.69 and specificity of 0.82. The serum levels of miR-8089 and miR-5698 were significantly associated with overall survival after the initiation of eribulin treatment. The present study provides evidence that serum miRNA profiling may serve as a biomarker for the responsiveness to eribulin and for predicting the development of new distant metastases in metastatic breast cancer.
Highlights
Breast cancer was reported as the most common cancer in 2013 [1] and the fifth leading cause of cancer death in 2016 [2] among Japanese women
Serum samples were collected from patients with recurrent or metastatic breast cancer 20 years of age who began eribulin monotherapy at National Cancer Center Hospital (NCCH) between January 2011 and December 2015
Before the initiation of eribulin monotherapy and after discontinuation of prior treatments, 147 serum samples were obtained from patients who were treated with eribulin after anthracycline or taxane
Summary
Breast cancer was reported as the most common cancer in 2013 [1] and the fifth leading cause of cancer death in 2016 [2] among Japanese women. The 5 year overall survival rate among breast cancer patients exceeds 90%, the treatment of recurrent or metastatic disease remains challenging [2]. Serum miRNA prediction for efficacy of eribulin. Japan Agency for Medical Research and Development (18ae0101013h0005)
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
